StockNews.com Initiates Coverage on Akari Therapeutics (NASDAQ:AKTX)

Stock analysts at StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research report issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Performance

Shares of AKTX stock opened at $2.72 on Thursday. The stock’s fifty day moving average is $1.97 and its two-hundred day moving average is $2.22. Akari Therapeutics has a fifty-two week low of $1.08 and a fifty-two week high of $5.50.

Institutional Trading of Akari Therapeutics

A hedge fund recently raised its stake in Akari Therapeutics stock. Omnia Family Wealth LLC raised its position in Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 87,628 shares of the biopharmaceutical company’s stock after acquiring an additional 28,511 shares during the quarter. Omnia Family Wealth LLC owned approximately 1.55% of Akari Therapeutics worth $273,000 as of its most recent SEC filing. 5.06% of the stock is currently owned by hedge funds and other institutional investors.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.